Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis
Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent newly developed oral antidiabetic drugs that are practiced for type 2 diabetes mellitus management and may decrease the risk of the first hospitalization in heart failure. The activity of SGLT2 inhibitors is not related to glucose, and the...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/6657380 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849401840705208320 |
|---|---|
| author | Ru-ping Cai Yu-li Xu Qiang Su |
| author_facet | Ru-ping Cai Yu-li Xu Qiang Su |
| author_sort | Ru-ping Cai |
| collection | DOAJ |
| description | Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent newly developed oral antidiabetic drugs that are practiced for type 2 diabetes mellitus management and may decrease the risk of the first hospitalization in heart failure. The activity of SGLT2 inhibitors is not related to glucose, and the effectiveness and safety of SGLT2 inhibitors in individuals with chronic heart failure (CHF) remain unclear. We systematically retrieved PubMed, Cochrane Library, Embase, NCKI, VIP, Wanfang Data, and ClinicalTrials.gov records to identify eligible trials. The primary endpoints were cardiovascular death/hospitalization for heart failure (CV death/HHF), cardiovascular death, and hospitalization for heart failure. Secondary endpoints included hypoglycemia, volume depletion, urinary tract infection, left ventricular ejection fraction (LVEF), and NT-proBNP. Nine randomized controlled clinical trials were included. Dapagliflozin was reported to significantly decrease CV death/HHF (relative risk (RR): 0.75; 95% confidence interval (CI): 0.68–0.84), CV death (RR: 0.80; 95% CI: 0.68–0.93), and HHF (RR: 0.72; 95% CI: 0.63–0.83). There was no effect on hypoglycemia (RR: 0.69; 95% CI: 0.34–1.40), volume depletion (RR: 1.17; 95% CI: 0.97–1.41), urinary tract infection (RR: 0.82; 95% CI: 0.43–1.57), LVEF (WMD: 0.53; 95% CI: −4.04–5.09), or NT-proBNP (SMD: −0.66; 95% CI: −1.42–0.10). The risk of CV death/HHF, CV death, and HHF was lower among patients receiving dapagliflozin than patients receiving placebo. |
| format | Article |
| id | doaj-art-8baf3ceefbc34990accde6a0ed4af9c7 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-8baf3ceefbc34990accde6a0ed4af9c72025-08-20T03:37:41ZengWileyCardiology Research and Practice2090-80162090-05972021-01-01202110.1155/2021/66573806657380Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-AnalysisRu-ping Cai0Yu-li Xu1Qiang Su2Department of Cardiology, Affiliated Hospital of Guilin Medical University, Guilin, ChinaDepartment of Cardiology, Affiliated Hospital of Guilin Medical University, Guilin, ChinaDepartment of Cardiology, Affiliated Hospital of Guilin Medical University, Guilin, ChinaSodium-glucose cotransporter-2 (SGLT2) inhibitors represent newly developed oral antidiabetic drugs that are practiced for type 2 diabetes mellitus management and may decrease the risk of the first hospitalization in heart failure. The activity of SGLT2 inhibitors is not related to glucose, and the effectiveness and safety of SGLT2 inhibitors in individuals with chronic heart failure (CHF) remain unclear. We systematically retrieved PubMed, Cochrane Library, Embase, NCKI, VIP, Wanfang Data, and ClinicalTrials.gov records to identify eligible trials. The primary endpoints were cardiovascular death/hospitalization for heart failure (CV death/HHF), cardiovascular death, and hospitalization for heart failure. Secondary endpoints included hypoglycemia, volume depletion, urinary tract infection, left ventricular ejection fraction (LVEF), and NT-proBNP. Nine randomized controlled clinical trials were included. Dapagliflozin was reported to significantly decrease CV death/HHF (relative risk (RR): 0.75; 95% confidence interval (CI): 0.68–0.84), CV death (RR: 0.80; 95% CI: 0.68–0.93), and HHF (RR: 0.72; 95% CI: 0.63–0.83). There was no effect on hypoglycemia (RR: 0.69; 95% CI: 0.34–1.40), volume depletion (RR: 1.17; 95% CI: 0.97–1.41), urinary tract infection (RR: 0.82; 95% CI: 0.43–1.57), LVEF (WMD: 0.53; 95% CI: −4.04–5.09), or NT-proBNP (SMD: −0.66; 95% CI: −1.42–0.10). The risk of CV death/HHF, CV death, and HHF was lower among patients receiving dapagliflozin than patients receiving placebo.http://dx.doi.org/10.1155/2021/6657380 |
| spellingShingle | Ru-ping Cai Yu-li Xu Qiang Su Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis Cardiology Research and Practice |
| title | Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis |
| title_full | Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis |
| title_fullStr | Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis |
| title_short | Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis |
| title_sort | dapagliflozin in patients with chronic heart failure a systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2021/6657380 |
| work_keys_str_mv | AT rupingcai dapagliflozininpatientswithchronicheartfailureasystematicreviewandmetaanalysis AT yulixu dapagliflozininpatientswithchronicheartfailureasystematicreviewandmetaanalysis AT qiangsu dapagliflozininpatientswithchronicheartfailureasystematicreviewandmetaanalysis |